Artera and Tempus are collaborating to expand access to Artera’s AI-based prostate cancer test. Currently connected to more ...

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, and Tempus, ...

Tempus AI (TEM) stock surged 13.4% on Thursday, hitting a new 52-week high of $86. The upside came after the health ...

Personalis shows promise in cancer detection but is years away from profitability. Read why PSNL stock is rated a hold with ...

Jennifer Doudna, a director at Tempus AI , Inc. (NASDAQ:TEM), recently sold a portion of her holdings in the company. According to a recent SEC filing, Doudna sold 1,320 shares of Tempus AI's Class A ...

Ryan M. Bartolucci, the Chief Accounting Officer of Tempus AI , Inc. (NASDAQ:TEM), sold 6,059 shares of the company's Class A common stock on February 13, 2025. The timing is notable as TEM shares ...

Tempus AI, Inc. , a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025.

During a Case-Based Roundtable® event, Neeraj Agarwal, MD, and participants discussed how they might determine which ...

Shares of Tempus AI rose by 13.36 percent on Thursday to close at $83.75 apiece as investors cheered the company’s partnership with the nonprofit organization Institute for Follicular Lymphoma ...

has been to expand a partnership with Tempus aimed at improving the big pharma's R&D productivity, starting with its cancer pipeline. US-based Tempus has built a precision medicine platform ...

PLC ("TC BioPharm" or the "Company")  a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has ...

Regarding the transaction, the lawmaker disclosed on January 14 the accumulation of 50 call options in Tempus AI with a ...